|
CLINICAL TRIALS IN LOW-COST COUNTRIES OFFER BIG SAVINGS, GSK SAYS
Moving human clinical trials to low-cost countries could save GlaxoSmithKline (GSK) more than $200 million annually in R&D costs, according to the drug giant’s top executive. This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives